March 5, 2019
Tag: Pancreatic Cancer Clinical Program
March 4, 2019
FierceBiotech: New strategies for improving pancreatic cancer treatments
March 4, 2019
Potential treatment strategy uncovered for pancreatic cancer
Scientists at UNC Lineberger discovered a technique to make pancreatic cancer cells reliant on one energy source and then starve them of it, which has led to clinical studies of a novel treatment strategy.
March 4, 2019
UNC Lineberger scientist launches mission to find more options for pancreatic cancer patients
Kirsten Bryant, PhD, launched a mission to find more treatment options for pancreatic cancer patients after losing her father, Bernard Elzer Jr., to the disease in 2013.
August 3, 2018
Researchers find potential key to unlocking the immune system in pancreatic cancer
In the journal Cancer Immunology Research, scientists led by UNC Lineberger's Yuliya Pylayeva-Gupta, PhD, revealed that a molecule called interleukin-35 plays a role in suppressing cancer-fighting immune cells in pancreatic cancer.
April 13, 2018
To starve pancreatic tumors, researchers seek to block ‘self-eating,’ other fuel sources
UNC Lineberger researchers led by Channing Der, PhD, are reporting preclinical findings for a potential two-treatment strategy to block multiple mechanisms of cancer cell metabolism in pancreatic cancer at the American Association for Cancer Research Annual Meeting in Chicago.
May 9, 2016
Der lab finds promising drug to fight pancreatic cancer
In the lab of Channing Der, PhD, researchers believe they have found a promising strategy to target a type of pancreatic cancer that is notoriously resistant to treatment—pancreatic cancer that has a mutation in a gene called KRAS.
March 10, 2016
Researchers share stories of their drive to fight pancreatic cancer
Kirsten Bryant, PhD, and Channing Der, PhD, shared personal stories of why they're driven to fight pancreatic cancer at the Pancreatic Cancer Action Network’s PurpleStride Leadership Breakfast in Durham, NC.
February 8, 2016
Device hits pancreatic tumors hard with toxic four-drug cocktail, sparing the body
A new implantable device delivers first-line treatment for pancreatic cancer directly to tumors, bypassing bloodstream and limiting widespread side effects. A team of researchers from the University of North Carolina including Drs. Jen Jen Yeh and Joseph DeSimone, has shown in preclinical research that the device can deliver a particularly toxic dose of drugs directly to pancreatic tumors to stunt their growth or, in some cases, shrink them. This approach would also spare the patient toxic side effects.
January 19, 2016
Preclinical study finds no benefit for diabetes drug in pancreatic cancer
UNC Lineberger researchers found in a study published in PLOS ONE that the diabetes drug metformin failed to show any benefit against pancreatic cancer, despite excitement about the drug for potential anti-cancer benefits. They believe the study shows the importance of testing new therapies in preclinical animal models that incorporate actual tumor tissue to better predict patient response.